Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
HIV
Interventions
DRUG

Nevirapine

"Standard medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medication.~The initial dose of NVP will be 6 mg per kg per dose orally twice daily until 42 weeks gestational age (2 weeks of age for infants born at term) which is the dosing selected by the NIH International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Network."

DRUG

Zidovudine

"An antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretroviral.~ZDV will be dosed as per standard guideline and routine practices."

DRUG

Lamivudine

"An antiretroviral medication used to prevent and treat HIV/AIDS. It is effective against both HIV-1 and HIV-2.~3TC will be dosed as per standard guideline and routine practices."

DRUG

LPV/r

"Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.~LPV/r will be dosed as per standard guideline and routine practices."

Trial Locations (1)

Unknown

Rahima Moosa Mother and Child Hospital, Johannesburg

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

University of Witwatersrand, South Africa

OTHER

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Columbia University

OTHER

NCT02431975 - Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial | Biotech Hunter | Biotech Hunter